Notice
Recent Posts
Recent Comments
Link
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 | 31 |
Tags
- Viking Therapeutics
- 노보노디스크
- structure therapeutics
- glp-1 비만
- tirzepatide
- GLP-1
- tern-601
- CAR-T
- Mash
- Nash
- Novo Nordisk
- Semaglutide
- survodutide
- VK2735
- lilly
- glp-1 비만치료제
- il-17 inhibitor
- nash/mash
- 자가면역질환 치료제
- 비만치료제
- orforglipron
- GPCR
- GLP-1 치료제
- 제약바이오
- 경구용 glp-1
- danuglipron
- gsbr-1290
- 바이오스터디
- VKTX
- Pfizer
Archives
- Today
- Total
목록2025/03/27 (1)
제약바이오 츄롸이츄롸이
Viking Therapeutics (NASDAQ: VKTX) - VENTURE Oral 임상 2상 등록 완료
https://ir.vikingtherapeutics.com/2025-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Pati13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Dail..
개별 스터디
2025. 3. 27. 18:00